Lupin Launches First Generic Version of Oracea® (Doxycycline Capsules) in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of first generic version of Oracea® (Doxycycline Capsules, 40 mg), in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA).

Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.

Doxycycline Capsules had estimated annual sales of USD 128 million in the U.S. (IQVIA MAT February 2024).

Shares of Lupin Limited was last trading in BSE at Rs. 1605.05 as compared to the previous close of Rs. 1612.65. The total number of shares traded during the day was 16818 in over 1541 trades.

The stock hit an intraday high of Rs. 1626.45 and intraday low of 1596.05. The net turnover during the day was Rs. 27125763.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Launch DoxycyclineCapsules USFDA Approval